Autologous Bone Marrow Transplantation - Blog Science Connections

ABMTinCRl 45
Induction
V A D
C- V A
D
MTX, L-ASP X 4
Consolidation Adriamycin + HD-ARA-C X 1
CBV + ABMT
maintenance chemotherapy
M-DOMP X 6
Figure 2. Treatment schema for ALL in first complete remission.
after high-dose cytarabine, bone marrow was collected for transplantation. The
median period between onset of remission and transplantation was 6 months
for AML and 7 months for ALL. After transplantation, when hematopoietic
recovery was complete, maintenance chemotherapy was restarted. After
transplantation six courses of AD-OAP were administered for AML and six
courses of MTX-DOMP for ALL.
The study of AML was originally designed as a randomized study between
transplantation and continuation of normal-dose chemotherapy without highdose
intensification. However, the randomization failed because patients
refused to enter the protective environment for the second time (remission
induction occurred in the protective environment) and because of the potential
risk involved in the CBV program. For this reason, patients were selected on a
voluntary basis. The study of ALL was a one-arm study that included treatment
with CBV.
For the first 10 days after transplantation, patients were treated with
acyclovir and with prophylactic antibodies to decontaminate the intestinal tract.